

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Siemens Molecular Imaging, Inc.	03/21/2013
RECEIVING PARTY DATA	
Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
Internal Address:	Patent Division
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	12372717
Application Number:	13676315
Application Number:	12661777
Application Number:	13035405
Application Number:	13477095
CORRESPONDENCE DATA	
Fax Number:	3172763861
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	patents@lilly.com
Correspondent Name:	Eli Lilly and Company
Address Line 1:	P. O. Box 6288
Address Line 2:	Patent Division
Address Line 4:	Indianapolis, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X19986 ETC.

502343177

PATENT
 REEL: 030393 FRAME: 0204

CH \$200.00 12372717

NAME OF SUBMITTER:	Linda M. Durbin
Signature:	/Linda M. Durbin/
Date:	05/10/2013
Total Attachments: 7 source=Siemens Assignment#page1.tif source=Siemens Assignment#page2.tif source=Siemens Assignment#page3.tif source=Siemens Assignment#page4.tif source=Siemens Assignment#page5.tif source=Siemens Assignment#page6.tif source=Siemens Assignment#page7.tif	

PATENT ASSIGNMENT AGREEMENT

This **PATENT ASSIGNMENT AGREEMENT** (this "Assignment"), effective April 3, 2013 ("Effective Date"), is made and entered into by and between Siemens Molecular Imaging, Inc., a Delaware corporation ("Assignor") and Eli Lilly and Company, an Indiana corporation ("Assignee") (each a "Party," and collectively, the "Parties"). Capitalized terms used herein but not otherwise defined herein shall have the meanings set forth in the Asset Purchase Agreement (defined below).

WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase Agreement, dated as of March 1, 2013 (as amended from time to time, the "Asset Purchase Agreement"), pursuant to which, among other things, Assignor agreed to sell, transfer, convey, deliver and assign to Assignee certain Acquired Business Intellectual Property, as more fully described in the Asset Purchase Agreement, on the terms and subject to the conditions set forth in the Asset Purchase Agreement;

WHEREAS, the Acquired Business Intellectual Property includes the patents and patent applications set forth on Schedule A hereto (collectively, the "Transferred Patents").

WHEREAS, in connection with the Closing, Assignor and Assignee have entered into that certain Bill of Sale dated as of even date herewith (the "Bill of Sale") pursuant to which, among other things, the Parties consummated the sale, transfer, conveyance, delivery and assignment to Assignee of the Transferred Patents; and

WHEREAS, Assignor and Assignee now desire to enter into this Assignment to effect and evidence the sale, transfer, conveyance, delivery and assignment to Assignee of the Transferred Patents.

NOW, THEREFORE, in consideration of the mutual covenants and promises hereinafter contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby, agree as follows:

1. Assignment. Assignor hereby sells, transfers, conveys, delivers and assigns to Assignee, and Assignee hereby purchases and accepts, all of Assignor's right, title and interest as such exists immediately prior to the Closing Date in and to the Transferred Patents, for the United States and for all foreign countries and jurisdictions (including, without limitation, all rights therein provided by international conventions and treaties), including, without limitation, any continuations, divisions, continuations-in-part, reissues, reexaminations, extensions or foreign equivalents thereof, and all other corresponding rights that are or may be secured under the Laws of the United States or any foreign country or jurisdiction, now or hereafter in effect, including, without limitation, the subject matter of all claims which may be obtained therefrom, together with all income, royalties, damages or payments accrued, due or payable following the Closing Date and the right, following the Closing Date, to the extent permitted in the Asset Purchase Agreement, to sue for, and collect damages by reason of past, present or future infringement, violation or other unauthorized use of the Transferred Patents, or

infringement, violation or other unauthorized use of the Transferred Patents, in each case, for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made.

2. Recordal. Assignor hereby authorizes and requests the Commissioner of Patents of the United States, and any other official of any applicable Governmental Authority, to record this Assignment and to issue any and all registrations from any and all applications for registration included in the Transferred Patents to and in the name of Assignee.

3. Further Assurances. Assignor shall timely execute and deliver any additional documents and perform such additional acts necessary, and shall use commercially reasonable efforts to perform, within a reasonable time, such acts that are desirable, to record and perfect the interest of Assignee in and to the Transferred Patents.

4. Counterparts. This Assignment may be executed in one or more counterparts, each of which when executed will be deemed an original, but all of which together will constitute one and the same instrument. The exchange by facsimile or other means of electronic transmission of executed counterparts of this Assignment will be deemed execution and delivery thereof.

5. Governing Law. This Assignment and its validity, construction and performance will be governed in all respects by the Laws of the State of Delaware applicable to contracts made and wholly performed in such state.

[Signature Page Follows]

IN WITNESS WHEREOF, the Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives.

SIEMENS MOLECULAR IMAGING, INC.
as Assignor

By:

Name: Dr. James Williams
Title: CEO Molecular Imaging

By:


Name: Christian Rummel
Title: CFO Molecular Imaging

Sworn to and subscribed before me
this 21st day of March, 2013.

Betty Cannon

Notary Public

My Commission Expires:



02-25-17

[PATENT ASSIGNMENT AGREEMENT]

ELI LILLY AND COMPANY
as Assignee

By: Jan M. Lundberg
Name: Jan M. Lundberg, Ph.D.
Title: Executive Vice President, Science /
Technology and President, Lilly
Research Laboratories

Sworn to and subscribed before me
this 1st day of April, 2013.

Diane C. Clene

Notary Public

My Commission Expires:

February 24, 2016

[PATENT ASSIGNMENT AGREEMENT]

Schedule A

PATENTS AND PATENT APPLICATIONS

<u>Internal File No.</u>	<u>Appln. No.</u>	<u>Patent No.</u>	<u>Country/Region</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Owner of Record</u>	<u>Action Required Within 60 Days</u>	<u>Lien or Outstanding Obligations (Excluding IP Licenses)</u>
2008P03744US	61/066,101	N/A	US	Imaging Agents For Detecting Neurological Dysfunction	02-14-2008		SMI	NONE	NONE
2008P03744US01	12/372,717	8,318,132	US	Imaging Agents For Detecting Neurological Dysfunction	02-17-2009	11-27-2012	SMI	NONE	NONE
2008P03744US02	13/676,315	N/A	US	Imaging Agents For Detecting Neurological Dysfunction	11-14-2012	N/A	SMI	NONE	NONE
2008P03744WO	PCT/US2009/000961	N/A	PCT	Imaging Agents For Detecting Neurological Dysfunction	02-17-2009	N/A	SMI	NONE	NONE
2008P03744WE	09711194.2	N/A	Europe	Imaging Agents For Detecting Neurological Dysfunction	02-17-2009	N/A	SMI	NONE	NONE
2008P03744WOCA	2715390	N/A	Canada	Imaging Agents For Detecting Neurological Dysfunction	02-17-2009	N/A	SMI	NONE	NONE
2008P03744WOJP	2010-546795	N/A	Japan	Imaging Agents For Detecting Neurological Dysfunction	02-17-2009	N/A	SMI	NONE	NONE
2008P03744WOKR	2010-7020589	N/A	Korea	Imaging Agents For Detecting Neurological Dysfunction	02-17-2009	N/A	SMI	NONE	NONE
2009P05072US	61/162,421	N/A	PCT	Imaging Agents For Detecting Neurological Disorders	03-23-2009	N/A	SMI	NONE	NONE
2009P05072US01	12/661,777	N/A	US	Imaging Agents For Detecting Neurological	03-23-2010	N/A	SMI	Received Notice of Allowance; Issue Fee Due	NONE

<u>Internal File No.</u>	<u>Applic. No.</u>	<u>Patent No.</u>	<u>Country/Region</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Owner of Record</u>	<u>Action Required Within 60 Days</u>	<u>Lien or Outstanding Obligations (Excluding IP Licenses)</u>
				Disorders				May 26, 2013	
2009P05072WO	PCT/US2010/028360	N/A	PCT	Imaging Agents For Detecting Neurological Disorders	03-23-2010	N/A	SMI	NONE	NONE
2009P05072WE	10723396.7	N/A	Europe	Imaging Agents For Detecting Neurological Disorders	03-23-2010	N/A	SMI	Divisional to be filed by May 1, 2013.	NONE
2009P05072WOCA	2756137	N/A	Canada	Imaging Agents For Detecting Neurological Disorders	03-23-2010	N/A	SMI	NONE	NONE
2009P05072WOCN	201080022125.4	N/A	China	Imaging Agents For Detecting Neurological Disorders	03-23-2010	N/A	SMI	NONE	NONE
2009P05072WOJP	2011-502177	N/A	Japan	Imaging Agents For Detecting Neurological Disorders	03-23-2010	N/A	SMI	NONE	NONE
2009P05072WOKR	2011-7025144	N/A	Korea	Imaging Agents For Detecting Neurological Disorders	03-23-2010	N/A	SMI	NONE	NONE
2011P03727US	13/035,405	N/A	US	Imaging Agents For Detecting Neurological Disorders	02-25-2011	N/A	SMI	NONE	NONE
2011P03727WO	PCT/US2011/029368	N/A	PCT	Imaging Agents For Detecting Neurological Disorders	03-22-2011	N/A	SMI	NONE	NONE
2011P03727WE	11711420.7	N/A	Europe	Imaging Agents For Detecting Neurological Disorders	03-22-2011	N/A	SMI	Response to EPO communication due 4/30/13	NONE
2011P03727WOCA	2794004	N/A	Canada	Imaging Agents For Detecting Neurological Disorders	03-22-2011	N/A	SMI	NONE	NONE
2011P03727WOCN	201180025561.1	N/A	China	Imaging Agents For Detecting Neurological Disorders	03-22-2011	N/A	SMI	NONE	NONE

<u>Internal File No.</u>	<u>Appln. No.</u>	<u>Patent No.</u>	<u>Country/Region</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Owner of Record</u>	<u>Action Required Within 60 Days</u>	<u>Liens or Outstanding Obligations (Excluding IP Licenses)</u>
2011P03727WOJP	PCT/US2011/029368	N/A	Japan	Imaging Agents For Detecting Neurological Disorders	03-22-2011	N/A	SMI	NONE	NONE
2011P03727WOKR	2012-7027668	N/A	Korea	Imaging Agents For Detecting Neurological Disorders	03-22-2011	N/A	SMI	NONE	NONE
2011P11325US	61/489,284	N/A	US	Imaging Agents For Detecting Neurological Dysfunction	05-24-2011	N/A	SMI	NONE	NONE
2012P06114US	13/477,095	N/A	US	Imaging Agents For Detecting Neurological Dysfunction	05-22-2012	N/A	SMI	NONE	NONE
2012P06114WO	PCT/US2012/061912	N/A	PCT	Imaging Agents For Detecting Neurological Dysfunction	10-25-2012	N/A	SMI	NONE	NONE
2012P25892US	61/721,629	N/A	US	Imaging Agents For Detecting Neurological Disorders	11-02-2012	N/A	SMI	NONE	NONE
2013P01035US	61/753,980	N/A	US	Imaging Agents For Detecting Neurological Disorders	01-18-2013	N/A	SMI	NONE	NONE
2012P10875US	61/644,053	N/A	US	Auto-radiography based Competitive Binding Assays for Compound Screening using Human Brain Tissue Sections	05-08-2012	N/A	SMI	Non-provisional filing due by May 8, 2013	NONE